Polypeptide With Localisation/Targeting Motif TRIZ Cases

An anti-B7H3 chimeric antigen receptor enables engineered T cells to bind and kill B7H3-positive tumor cells.

An oncolytic adenovirus encodes a B7 transgene to deliver co-stimulatory signals directly to infected cancer cells.

Humanized anti-HLA-A2 antibodies direct chimeric antigen receptors to enhance immune tolerance and reduce transplant rejection.

Chimeric VIP antagonist peptides block VIP signaling to enhance T cell proliferation and anti-leukemia responses.

Optimized CDR regions in antigen binding molecules enable specific binding to GGGS linker sequences, overcoming low affinity and non-specific binding issues.

Luteinizing hormone receptor binding agents isolate primitive hematopoietic stem cells using multi-marker selection, reducing conditioning toxicity.

Multi-domain CARs merge signaling pathways to eliminate radioiodine-refractory thyroid tumors.

Segmented JNK inhibitors use D-amino acids to resist proteolytic degradation while retaining L-amino acid binding capacity for therapeutic efficacy.

SmartBac baculovirus expression system merges gene cassettes into single plasmids via Cre-loxP recombination, resolving cumbersome cloning workflows.

PDGF-DD ligand activates NKp44 receptors on natural killer cells, resolving elusive ligand gaps and enabling targeted tumor growth arrest.

Amino acid mutations in Protein L domains resist NaOH degradation, preserving selectivity during repeated chromatography regeneration.

M2SR recombinant influenza virus platform expresses heterologous antigens to stimulate comprehensive immune responses.

Chimeric autoantibody receptor T cells express desmoglein domains to selectively bind and eliminate autoreactive B cells.

CAR-engineered NK cells use scFv or variant ACE2 to bind the SARS-CoV-2 spike protein, addressing inadequate viral entry neutralization by existing therapies.

Deleting alkaline and neutral protease genes prevents enzyme degradation, increasing relative activity by 150% to 700%.

A transgenic maize plant expresses an endoplasmic reticulum-targeted aflatoxin-degrading enzyme to reduce toxin levels in kernels.

A recombinant fusion protein localizes therapeutic agents to the vascular endothelium via high-affinity EPCR binding.

Cell cycle regulation and preliminary anti-action shift repair pathways from non-homologous end joining to homology-directed repair.

S309-CAR-NK cells target coronavirus spike proteins via specific scFv binding, resolving safety and efficacy trade-offs in antiviral therapy.

YESS methodologies evolve mutant kinases to identify resistance mutations, enabling prediction of therapeutic efficacy loss and mitigation of clinical failure.

Engineered rodents expressing human Fc regions and receptors resolve poor predictive accuracy of conventional models for therapeutic agent safety.

Segmented bi-specific CARs target CD138 and BCMA antigens to overcome treatment resistance in multiple myeloma.

Segmentation reduces enzyme size for vector delivery while maintaining specificity.

Optimizing cell culture pH and signal peptide codons to minimize low molecular weight species in recombinant protein compositions.

Specific tat-M2NX peptides target the TRPM2 channel binding pocket, resolving gender-specific efficacy gaps in stroke treatment.

A modified G-CSF precursor with specific signal peptide mutations ensures precise processing and high yields of full-length protein.

Engineered spike ectodomain polypeptides enhance stability and production yield through targeted amino acid mutations.

ZEBRA-derived cell penetrating peptides transport diverse cargo molecules into cells via optimized amino acid sequences.

Antibodies bind non-randomized fibronectin type III domains to detect chimeric antigen receptors on T-cells.

Engineered chimeric antigen receptors eliminate fibroblast activation protein-expressing stromal cells to reduce tumor burden.

SOSIP trimer immunization overcomes antigenic diversity to reliably elicit broadly neutralizing bovine antibodies.

Modified Bip signal sequences enhance heterologous protein secretion by resolving ER membrane dissociation bottlenecks during translocation.

Transformed Bifidobacterium displays coronavirus proteins to induce immunity, bypassing ultra-low temperature storage requirements.

A continuous counterflow centrifuge system creates a fluidized bed of cells to enhance transduction efficiency.

Segmenting the editing system into a compact RDDP and Cas protein reduces vector delivery complexity while maintaining high editing efficiency.

Fusing antibody mimetics with colicin polypeptides creates a targeted antibiotic that kills bacteria via ion channels.

Bi-specific CARs target NKG2DL and CLDN18A2 antigens to improve killing efficiency while reducing off-target toxicity.

Administers BTK inhibitors alongside CAR-T therapy to overcome tumor evasion mechanisms and maintain T cell proliferation in B cell malignancies.

Optimized CD19-specific CAR variable regions improve cytotoxic activity against B cell malignancies in refractory acute leukemia patients.

PEG receptors on engineered cells bind exogenous polyethylene glycol to amplify activation signals, resolving low antigen abundance in solid tumors.

Site-specific immune privilege reduces inflammatory responses and minimizes systemic side effects during transplantation.

Modified AMH proteins preserve ovarian reserve by inhibiting premature follicle depletion during gonadotoxic treatments.

Specific CD47 antibodies resolve binding insufficiency by enabling CAR-mediated phagocytosis of tumor cells.

CUPID A peptide traverses membranes to deliver cargo while retaining bioactivity.

Segmenting CARs into alpha, beta, and gamma chains improves signal transduction efficiency while reducing background activation in ROR1-positive cells.

Chimeric antigen receptor integrates glucocorticoid-induced TNF receptor intracellular domain to enhance cytotoxic activity.

Chimeric HLA accessory receptor targets mismatched HLA to eliminate alloreactive T cells, reducing transplant rejection and GVHD risk.